Insight

Vivek Subbiah: N-of-1 Trials in Cancer Drug Development

Photo from Vivek Subbiah/X

Jul 15, 2024, 04:56

Vivek Subbiah: N-of-1 Trials in Cancer Drug Development

Vivek Subbiah shared a post on LinkedIn about a recent paper titled “N-of-1 Trials in Cancer Drug Development “ published in the AACR journals.

Authors: Mohamed A. Gouda, Lars Buschhorn, Andreas Schneeweiss, Adam Wahida, Vivek Subbiah.

“Pleased to share our paper in AACR Journals Cancer Discovery on ‘N-of-1 Trials in Cancer Drug Development’.

The current approaches for cancer drug development lag behind an accelerated need in the field for a fast and efficient method for evaluating drugs in the personalized medicine era. .

In that regard, N-of-1 studies emerge as a potential addition to the drug development arsenal, although there are several considerations before its broad application becomes feasible. In essence, N-of-1 trials are a departure from the traditional ‘drug-centric’ model to a ‘patient-centric’ model.

Herein, we review the concept of N-of-1 trials and provide real-world examples of their use in the developmental therapeutics field. N-of-1 trials offer an exceptional opportunity for fast-tracking of cancer drug development in the precision oncology era.”

Source: Vivek Subbiah/LinkedIn

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.